An overview of the state-of-the-art in predictive modelling of compound combination activity and the value and significance of systems informatics in identifying combinations for therapeutic purposes.
Introduction and background
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be it drug combination therapy for treating complex networkdriven diseases such as cancer [1, 2] or antifungals and antibiotic combinations targeting infectious diseases [3, 4] .
This popularity can be attributed to multiple factors, which include overcoming drug resistance [5, 6] and multitargeted therapies for perturbing multiple nodes of pathway(s) of interest for better efficacy [7] . Synergistic drug combinations aside, there is also a crucial need to study compound combinations towards understanding the toxic effects of chemical mixtures, either in a drug-drug combination, for example carbamazepine toxicity in combination with several drugs and inhibitors [8, 9] , or a drugnatural-product combination, for example the well-studied impact of grapefruit juice on the bioavailability of certain drugs [10, 11] . Combination therapy has also been extensively studied in traditional Indian [12] and Chinese medicine [13] , as has the impact of these traditional medicines when administered in combination with Western medicine [14, 15] .
Compound combination behaviour can be broadly classified as synergistic, antagonistic or additive. Synergy, in this context, is the result of combining two or more chemical compounds to produce an effect that is greater than additive effects (where additive effects are computed from the individual effects based on specific mathematical models) [16] . The use of compound combinations can be either beneficial to the biological system these are intended towards, as in the case of combination therapy [1] , or produce an intended harmful effect, as found for antifungals [17] , or an unintended harmful effect, such as for synergistic toxicity [18] . By contrast, antagonism is the phenomenon when a compound combination produces an overall effect that is less than the additive effects of the individual compounds.
Despite the significance of compound combinations in therapeutic and toxicity studies, the ability mechanistically to explain and model compound combinations in a systematic fashion is currently limited. Published reviews discuss the urgent need for multitarget therapeutics and systematic approaches to identify communication hubs between pathways that can be targeted by drugs [6, 19] . However, the approach taken to map and understand the systems level view of the organism or disease comprehensively is expensive, time consuming and not necessarily feasible. Although there have been several reports that elucidate the mechanism of action (MOA) of a compound combination [20] [21] [22] , most reports focus on observational studies of a limited number of combination effects in specific organisms and diseases. Table 1 provides a list of studies that have followed gene-expression-, pathway-annotations/network-and modelling-based approaches towards assessing compound combinations across different disease areas, as well as generalised studies. A similar table listing complementary studies can be accessed in a recent publication by Ryall and Tan [23] . The dynamics of networks of pathways can be investigated through the use of mathematical network models, and the outcome of potential target inhibition within the model can be compared to assay readouts to allow MOA hypothesis generation of a combination [24, 25] . These models could make use of large-scale datasets of compound combination responses. Even though limited in terms of availability, opportunities to train and test predictive models can be provided. Table 2 provides a list of publicly available combination data resources or datasets. This information, along with available large-scale chemical and biological resources in the public domain (Table 3) , could be used to construct an integrated pipeline to assess compound combination behaviour. Combining the chemical and biological fingerprints mentioned above, along with gene expression profiles in disease cell lines, wherever available, could add further weight to such analysis. However, there are still certain aspects of data missing that are crucial to assessing combinations. For example, many datasets only consider single doses, and thus could prevent appropriate quantification of synergistic (or antagonistic) behaviour using classical methods. In addition, if the dosage is not therapeutically relevant, it might not be suitable for translational development.
Following such an integrated approach, as described in this section, Fig. 1 suggests a modelling pipeline towards predicting the synergistic and/or antagonistic behaviour of compound combinations. The aim of this pipeline is to integrate and explain the observations from combination assays. For a suggested compound combination, the model will be able to search bioactivity space and integrate available chemical and biological information that includes network and pathway annotations, gene expression profiles and chemical fingerprint similarities. This could help identify patterns that contribute towards synergy predictions for the compound pair, as well as develop a MOA hypothesis for the combination. These predictions could then be further validated by in vitro and/or in vivo experiments. This review explores the challenges, limitations and, more importantly, the value and perspectives of predictive modelling of compound combination effects in therapeutic development and toxicological studies.
Applications and impact of drug combinations
The applications of studying and analysing the synergistic, additive or antagonistic behaviour of compound combinations can be manifold. These range from therapeutic applications, such as drug combinations, to counter selectivity and resistance, to assessing safety of household chemical combinations through toxicity studies. Drug-target selectivity has long been a high priority, yet not always achievable, part of the drug discovery pipeline [26] . However, many kinase inhibitors and central nervous system (CNS)-active drugs exhibit promiscuity that is often crucial to achieve better efficacy [27, 28] . In a study by Lehár et al., the authors performed large-scale simulations of bacterial metabolism and $94,000 multidose experiments across multiple diseases to show that synergistic drug combinations display higher specificity to certain cellular contexts than single agent activities [29] . Furthermore, results validated in a rat model showed that the antiinflammatory drug prednisolone and the antidepressant nortriptyline display therapeutic synergy, but not toxicity. Selectivity in this case was achieved through the differential expression of the proteins targeted by these drugs in stimulated peripheral blood mononuclear cells (PBMCs). This evidence could have broad implications in identifying and studying therapeutically relevant selectivity for drug combinations.
Combination therapeutics have also been utilised as an approach to overcome drug resistance of pathogens [21] . This strategy has been popular in antimalarial and antituberculosis drug discovery and usually involves the first drug acting on mutants resistant to the second drug when administered together [30, 31] . Drug combinations are a standard-of-care in many cancers, by : a toxicity forecaster resource [134] combining drugs that act on pathways essential for the survival of the cancer cell but not the normal cell [32] [33] [34] . Recent publications on tumour heterogeneity and clonal evolution in cancer further support such practice [35, 36] . Genetic diversification as the tumour evolves pointed to distinct and multiple mutations across the same tumour specimen. Identifying and administering drugs that could bypass the resistance mechanism of all such identified mutations could not be realistic, because patient tolerability to the large number of drug combinations would have to be very high. However, such studies provide an opportunity to identify oncogenic pathways that contribute most towards the tumour progression. This could help prescribe a carefully selected drug cocktail at tolerable doses, which would be a significant step towards tackling tumour heterogeneity.
Compound combinations are also a popular approach for antibacterial and antifungal therapy [4, 37, 38] . Hill et al. evolved experimental populations of Candida albicans and Saccharomyces cerevisiae with a combination of heat shock protein Hsp90 inhibitors and widely used antifungals: the azoles [38] . This helped the authors identify mutations that evolved as a consequence of the combinations, understand resistance mechanisms as well as suggest strategies that could bypass the resistance. Apart from bypassing drug resistance, the aim is also to achieve greater efficacy utilising lower-dose combinations compared with higher-dose monotherapies. Numerous studies that show the greater efficacy displayed by compound combinations compared with monotherapy have been published [3, 6, 39] . This could potentially result in lower risk of side-effects and, hence, better quality of life [40] [41] [42] .
Tolerability is of prime concern to the medical and scientific communities. A recent review discusses the advantages of fixeddose combination therapies relative to monotherapy in the context of type-2 diabetes treatment [43] . These include greater efficacy, reduced risk of adverse reactions and lower overall costs. There are several contributors to determine whether drug combinations do indeed reduce the risk of adverse reactions; one of which is if a pathway targeted by a drug also contains off-targets that would cause an adverse reaction.
The rational discovery of novel drug combinations can be expedited by predictions of combination effects based on data generated from these experimental studies. Such predictive models could utilise combination data across disease areas, which could be another key step towards efficacious multitargeted therapies. This will not only provide an opportunity to exploit the unexplored and available bioactivity space but could also help identify novel and unexpected synergistic drug combinations [19, 39] . 
In vitro/in vivo validation
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FIGURE 1
An integrated approach for analysing compound combinations using chemical and biological fingerprints. For compound combinations, the model will be able to search the bioactivity space along with integrating network and pathway annotations, gene expression profiles and chemical fingerprint similarities. This will lead to synergy predictions and developing a mechanism of action hypothesis for the combination that could be further validated by in vitro and/or in vivo experiments.
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Identifying synergistic compound combinations
Recent developments in high-throughput approaches to combination screening have enabled scientists to explore large collections of compound combinations experimentally. However, even with sophisticated automation systems, the number of combinations screened is a small fraction of the possible number of combinations. Strategies for experimentally determining the possible effect of drug combinations can range from screening several compounds at a time from a large database to exhaustive pairwise screening [44] [45] [46] such that an effective combination can be found. There have been several reports of large-scale combination screening campaigns. Borisy et al. [47] provided the earliest report of a systematic, large-scale screen of $120,000 compound combinations using a proprietary platform. More recently, Mathews Griner et al. [20] have described the National Centre for Advancing Translational Sciences (NCATS) high-throughput platform for combination screening which screened thousands to tens of thousands of combinations in a checkerboard format (i.e. all combinations of two drugs at n doses each). Subsets of the data generated by this platform are publicly available (https://tripod.nih.gov/ matrix-client/). Although such high-throughput platforms are crucial for running large numbers of combination experiments in a reasonable timeframe, they are expensive, especially if one considers replicate data and high-resolution checkerboard patterns (i.e. ten or more doses per drug resulting in 100 or more individual dose combinations). As a result, there are two roles for computational approaches in this area. Firstly, when faced with a large collection of combination responses, we wish to have computational methods that can characterise the combinations quantitatively, thus enabling ranking and filtering. Secondly, we desire to identify useful drug combinations prospectively, initially focusing on pairs of drugs but also higher-order combinations.
Approaches to the characterisation of combination responses
When characterising combination responses we propose and employ a two-step process. First, given the large number of combinations tested in a high-throughput setting, we must employ quality control (QC) metrics to ensure that only robust combination responses are considered for downstream analysis. Dispense errors, batch effects and edge effects can introduce noise and artefacts on screening plates, which result in noisy or incomplete responses [48] . In a high-throughput setting each plate includes positive and negative controls, and these can be used to derive plate-level QC metrics. Examples of such metrics include the Z 0 , signal:background ratio and coefficient of variation [49] . Such metrics can indicate that all combinations on a plate are to be rejected. However, there are cases where the plate controls perform well but a few combinations on the plate are affected by a screening artefact (such as a localised well dispense error or problems at high concentrations). As a result, it is useful to employ combinationlevel QC metrics. Currently, there are no published guidelines for such metrics. The NCATS platform has implemented a heuristic QC score [50] that is useful for identifying poor-quality combination responses. This score takes into account the quality of the single agent dose responses, the absence of randomness in the dose combination sub matrix (as measured by spatial autocorrelation) and thresholds for no activity and variance of combination response (Fig. 2) . Whereas the method employs several empirically selected thresholds, its use allows one to filter out severely compromised combination responses rapidly.
Having performed screening QC on the set of combination responses, the next step is to characterise the combination effect as potentially synergistic or antagonistic. There is rich literature on the topic of such quantification starting with Loewe, Bliss and Berenbaum [51] [52] [53] . Underlying all these models is the assumption 
FIGURE 2
Examples of noisy (left) and well-defined (right) response surfaces that are characterised by the QCScore heuristic [50] . This score is useful for identifying and filtering poor-quality combination responses. The colour of each cell represents the assay response at that dose combination where black is no cell death through to red being full cell death.
that the combination effect of two drugs is purely additive -with the actual definition of additivity being model-dependent. Synergy (or antagonism) is then characterised as a deviation from additivity. The Loewe additivity model is mathematically characterised by the isobole equation. It can be interpreted as modelling synergy as a departure from dilution effects [53] . Assume for instance that specific doses of drugs A and B produce a given effect (e.g. 50% inhibition). According to the isobole equation, if drugs A and B are additive then there exist several combinations of drugs A and B at reduced doses that should produce the same effect. For instance, half the dose of A combined with half the dose of B or one-third of the dose of A combined with two-thirds of the dose of B should produce the same effect as A or B alone. Synergy with respect to this model can be visualised using an isobologram (Fig. 3) , which displays the dose (in IC 50 units) of drug A and B required to achieve a specified effect level. The red dashed line indicates additivity, the line below the diagonal is indicative of a synergistic combination and the line above the diagonal is that of an antagonistic combination. Berenbaum [51] and Chou [54] have defined the combination index (CI) as a way to quantify synergy based on the Loewe model. The CI corresponds to the sum of the ratio of the amount of drug A used in combination to the amount of drug A required as a single agent for a specific effect (usually 50%) plus the corresponding ratio for drug B for the same effect. A CI <1 indicates synergy and CI >1 indicates antagonism. This model has been used by Chou (the Chou-Talalay method) [54] to define several metrics and graphical representations such as the median effect curves. It is important to note that the Loewe model is not really applicable when the two compounds do not produce a dose-response with the same maximum effect or even when the shapes of the doseresponse curves differ [55] .
The Bliss model defines synergy as a departure from independent compound effects [52] . Importantly, the model states that the drugs act in an independent fashion and that there are no effects because of drug-drug interactions (DDIs). Thus, according to Bliss independence the fractional response of the combination is the sum of the fractional responses of the individual drugs minus their product (Equation 1). Although simple in nature, the model is not considered to be robust in many situations, because it often characterises combinations of a compound with itself as synergistic.
where PE A,B is the predicted combined effect of compounds A and B, E A is the known effect of compound A and E B is the known effect of compound B. Finally, the Gaddum non-interaction reference (or highest single agent) model simply defines additivity as the larger of the two single-agent responses. Although a very simplistic model it is applicable when the targets of the two compounds have no functional relation, so that compounds elicit their effects entirely independently of one another. See [56] for a detailed discussion of these and other models.
In general, given a combination screen, one selects a model and for each tested dose-combination the model is used to predict a combination response. If the observed response is less than or greater than the predicted response one makes a call of synergistic or antagonistic, respectively. For checkerboard style screens, the differences from the model can be visualised in a heatmap, or otherwise summarised by a scalar value [44] . However, with multiple models available, it is not always clear a priori which model should be used to quantify a particular experiment. In some cases, authors simply report the results from multiple models; whereas Lehár et al. [24] employ multiple models and use a x 2 test to select the best-fitting model. The definition of a generalisable, robust model of additivity is therefore still an open problem; however the latter approach appears to tackle the problem in the most reasonable manner.
Evaluating and analysing combination data
Methods to predict combination effects can easily identify hundreds of drug combinations that are predicted to be efficacious or synergistic. Table 4 provides a list of well-known, publicly available software (free as well as commercial) for analysing combination data. After appropriate in silico validation techniques one would, ideally, perform experimental validation of the compound combination model that has been generated. There are a multitude of techniques to evaluate combination effects. Some of these approaches can be performed in high throughput, such as checkerboard approaches described by Mathews Griner et al. [20] and Borisy et al. [47] , whereas other methods such as fixed-dose ratio [54] methods are generally more time consuming (but can be accelerated using robotic automation systems or miniaturisation technologies) [57, 58] . Several in silico studies have performed validation of retrospective or prospective predictions. A matrix imputation approach was employed to predict synergistic target pairs that were then perturbed using small molecules [59] . A key feature of this approach is that it estimated the propensity of two targets to exhibit synergism and, in combination with the imputation framework, selected a subset of the entire collection of targets that, when screened, will identify a significant fraction of synergistic pairs. Importantly, the 
FIGURE 3
Synergy can be visualised using an isobologram, which displays the dose (in IC 50 units) of drugs A and B required to achieve a specified effect level. The red dashed line indicates additivity, the line below the diagonal is indicative of a synergistic combination and that above the diagonal is an antagonistic combination.
formulation of this approach is sufficiently general so that one can replace targets with compounds. The results of the algorithm were validated using published data as well as on a set of five in vitro glioblastoma cell lines. By contrast to purely computational approaches, the combination of an evolutionary algorithm (EA) and iterative testing was used to identify combinations of anti-inflammatory molecules [60] . In this work, the top-ranked computational predictions (made by the EA) were experimentally tested and those results were then fed back into the EA. As a result, the authors were able to find combinations with significantly improved anti-inflammatory activities after testing just 550 combinations (out of a possible nine-billion combinations).
Metabolic network analysis of gene targets in Leishmania major has been employed to identify combinations of FDA-approved drugs [61] . This approach also identified synthetic lethal targets and validated four combinations against these target pairs in an in vitro model of L. major. Another network-based approach [34] used drug inhibition and target binding data to identify relevant targets for combination therapy. The computational results were validated using siRNA knockdown of single targets and target pairs. An approach that quantified crosstalk in target networks of drug pairs [62] was then used experimentally to verify the synergistic effects of curcumin when combined with multiple drugs, including capsaicin and celecoxib, in a rat model of myocardial ischaemia.
Miller et al. [63] employed a drug combination screen along with phosphoproteomics measurements to develop a computational model of the signalling network that explained the observed synergy (epistasis) between insulin-like growth factor 1 receptor (IGF1R) and cyclin-dependent kinase (CDK)4. The model was then used to predict that combined inhibition of these targets would reduce activity in the Akt pathway, which was subsequently experimentally confirmed. This is also an example where network models could help explain unexpected synergistic observations, as well as identify new perturbation points in a network that could be targeted by a combination of inhibitors.
Finally, high-content approaches have also been used to identify candidate drug combinations. An example is the construction of multivariate profiles of compound activity in triple-negative breast cancer (TNBC) cell lines using high-content imaging [64] . These profiles were then used to compute profile similarity scores between small molecules, which were subsequently used to predict five candidate combinations in multiple TNBC cell lines. Of these, vinblastine and ispinesib showed synergism in three TNBC cell lines but not in normal fibroblasts. A mouse model confirmed their antitumour activity, with the finding that the combination reduced tumour growth significantly when compared with monotherapy.
Utilising gene expression and pathway annotations in predictive models
Microarrays are an accessible, cost effective and fast way of measuring cellular responses and gene expression profiles [65] , which facilitates research with the aim to understand regulatory networks on the basic level, as well as when applied in a drug discovery context [66] . In recent years, this approach has been utilised to predict synergistic effects of drug combinations on cancer cell lines, given gene expression profiles of individual drug treatments. In the following case studies we point out a functional enrichment analysis method and an enhanced Petri-net (EPN) model for assessing synergistic effects of compound combinations. The former study utilises cellular profiling of 14 individual drug responses for predicting synergy or antagonism of drug combinations [67] . In this study, differentially expressed genes after treatment of each of the 14 drugs on human b-cell lymphoma (DLBCL) cell line (LY3) from the NCI-DREAM Drug Sensitivity Prediction Challenge [68] represented the drug signature. It was hypothesised that correlated drug signatures should predict synergistic effects, whereas anticorrelation of those signatures indicates antagonism. The rank-ordered list of predicted synergistic drug combinations was compared to a gold standard experimental (in vitro) ranking of compound combinations provided in the challenge, and a measure of concordance (concordance index) was used to score the validity of prediction. In an effort to improve the method, functional enrichment analysis was applied on the overlapping gene signature of each paired drug mapped to protein interaction network to check interaction of the proteins produced by those genes. The network approach improved the performance of the model significantly. In the second case study, an EPN model was designed to explain mechanism of synergy of compound combinations from individual compound treatment transcriptional responses [69] . The EPN was applied on gefitinib and docetaxel and was capable of explaining mechanism of observed synergistic effects to a good extent. For this purpose, the effect of each drug on gene expression was depicted in the EPN with tokens and transitions in different colours, which illustrated the mechanism of synergy. Also, gene expression data of treatment of different doses of each of the two compounds (in a total of 16 different concentrations) was provided to the model. The model successfully predicted the effective dose, and predicted genes involved in the mechanism of synergy using each concentration. However, as a major limitation the model has been validated on only one particular drug combination studied here. Also, the authors acknowledge that, for the EPN model to work efficiently, knowledge of the targets and downstream signalling pathway annotations are necessary. Irrespective of the fact that this study utilises large-scale resources populated with network biology annotations, these annotations are not always available in certain cases.
Gene expression data have also been beneficial in designing models for predicting chemosensitivity of three widely used drugs as a single agent or in combination [70] . Cisplatin, paclitaxel and gemcitabine were tested on 40 human urothelial cancer cell lines in vitro and cell lines were labelled resistant, sensitive or intermediate for each of the drugs. Differentially expressed genes were derived after application of each drug on each cell line. Among them, genes that were able to differentiate between resistant and sensitive cell lines were identified for each of the three drugs. The accuracy of sensitivity prediction was estimated between 93% and 96% for each of the drugs across cell lines. The probability of sensitivity of drug combination was estimated by multiplying probabilities calculated for each individual drug, and the accuracy of synergistic drug combination predictions was hence assumed to be around 80%. Even though the probability of sensitivity of drug combinations was predicted robustly, the model is less successful in predicting the synergy of cytotoxic effects of combinations. Moreover, extrapolation of the method to other cell lines or drug combinations requires generation of extensive in vitro drug response data for each combination. In a similar study, kinases that drive tyrosine kinase inhibitor (TKI) resistance in non-small-cell lung cancer (NSCLC) cell lines were identified by integrating data from genetic screens and RNAseq analysis [71] . This analysis led to the identification of the chronic myelogenous leukaemia (CML) drug bosutinib as an efficient inhibitor that could induce apoptosis in TKI-resistant cell lines. Further analysis led to the identification and validation of the synergistic effects of the combination of bosutinib and gefitinib in gefitinib-resistant NSCLC cell lines and suggests a good opportunity for drug repurposing. These studies suggest that gene expression data of individual compound treatments have potential for predicting synergism and sensitivity of compound combinations. An algorithm called TIMMA provides an integrated workflow that employs chemical bioactivity and cell line sensitivity data, towards predicting synergy for drug combinations and the proteins that these drugs could target [34, 72] . However, predicting synergism and sensitivity of drug combinations on a large scale still remains a challenge. Large-scale databases of gene expression data on individual compound treatments are publicly available such as the Connectivity Map [73] (1309 compounds) and LINCS (20,413 compounds) (http://www. lincscloud.org/). This could also be an interesting opportunity to benefit from individual compound treatment databases for predicting synergism and sensitivity of compound combinations on a much larger scale.
Genetic and RNA interactions to guide the design of compound combinations
The effect of a single compound on a biological system can be thought of as an amalgamation of its effects on different (protein) targets. The effect of a combination is therefore a complex function of the protein interactions of each individual compound. In a localised example, it was shown that the protein dynamics of a system can be described simply by the linear superposition of the perturbations of the individual compounds [74] ; this result is intriguing yet the phenomenon of synergy and antagonism suggests that any combination effects are unlikely to be linear in general. However, chemical perturbation is by no means the sole process by which a biological system can be modulated. Genetic perturbations in the form of gene knockout often have similar effects to the application of targeted drugs (although the behaviour of drugs is much more complex owing to dose and bindingsite elements) and have been used as a useful biological probe in classical genetics. Yet, because gene interaction networks can be used to predict the effect of a combination of knockouts on the resulting phenotype, for example epistasis, they could also provide insight into synergy, and have been used as a context for exploring drug combinations [75] . Chemical-gene interactions (from single compound screening against a library of mutants) have been carried out in S. cerevisiae, and lead to several MOA discoveries [76] . These could potentially be exploited through the replacement of the genetic deletion with a targeted compound [37] .
The development of RNAi yields another biological perturbation technique, because knockdown of a gene also often has a similar effect to a drug targeting the product of the same gene (although variation in time and dosage elements can confound this picture). Double or even higher-order knockdown experiments, known as combinatorial RNAi (coRNAi) [77] , are an RNAi equivalent to compound combinations. These have been investigated to the third order by Sahin et al. [78] with no unintended silencing or cytotoxicity supporting the viability of the technique. coRNAi treatments might be deployed directly (they are currently being investigated as a treatment for hepatitis C) [79] , but can prove even more powerful by providing an added insight into the effect of compound combinations, by matching their underlying biological perturbations; it is possible a combination of the two approaches could prove even more potent [75] .
To summarise, whereas there are important differences, mRNA knockdown and gene knockout are related biological perturbation methods to chemical-protein interaction. According to this notion of potential equivalence, it might be possible to consider a broader 'biological combination', allowing data from these different biological facets to be integrated into a single, more descriptive model. Data integration of this nature has proved fruitful in other data-driven fields such as network biology, for example the integration of gene regulatory and protein-protein interaction networks [80] , and thus might also be conducive to progress in modelling the effect of compound combinations.
Combinations as an investigative tool
Although the main interest in compound combinations is as a prospective avenue for therapeutics, there is also strong potential in research as an investigative probe of biological network structure. The concept is similar to synthetic genetic array analysis [81] , which employed combinations of double genetic knockouts to locate genes that interact nonadditively with regard to phenotype. This observed phenomenon, termed synthetic lethality [82] , shares certain parallels with chemical synergy. Mapping these interactions led to the production of gene-interaction networks [83] as a useful representation of biological space [84] . Taking advantage of the relatedness of inhibition of a gene product, and the knockout of the gene itself, the methodology was adapted by replacing one knockout with a panel of drugs with known protein targets, known as combination chemical genetics [75] , to test for 'synergy' in knockout-compound pairs. The techniques have been used to derive MOA hypotheses in yeast: for example, the antianginal drug molsidomine was found to target lanosterol synthase [85] . The use of chemical perturbation is (idealistically) preferable to genetic perturbation; whereas library design is difficult because of ADMET, selectivity and many other problems, in that in many cases chemical perturbation studies are faster, simpler and easier, allow for the perturbation of essential genes and, finally, a dose-response curve can be obtained, which describes the response of the biological system during gradual modulation of a target -a crucial distinction to most genetic approaches. The natural progression was then the replacement of the second knockout with another drug panel, essentially now a pairwise screen of drug-drug combinations. A synergistic drug-drug surface not only encodes a genetic interaction but a study found the surface itself provided deeper insights into the relationship [86] . In fact, it was found that it was possible to classify the local network topology of the drug targets according to the relative shape of the response curve [24] , paving the way for more-detailed interaction networks.
Modelling drug-drug interactions
Up to 30% of adverse drug reactions are caused by DDIs. The ability to model DDIs could play a significant part in understanding the behaviour of compound combinations, as well as contributing to the identification of novel synergistic chemical pairs. When administered together, DDIs can result in a reduction in efficacy (antagonism), an increase in toxicity of either or both drugs (synergistic toxicity) or a previously unobserved effect that is unrelated to either drug taken by itself (coalistic) [87] . Patients who take multiple drugs are often afflicted with multiple comorbidities, and it is difficult to determine whether adverse events are the result of side-effects from a single drug, interactions between two or more drugs or exacerbations of the patient's underlying disease(s) [88] . DDIs could have a direct impact on the bioavailability of drugs, as well as their ADMET and drug metabolism and pharmacokinetic (DMPK) properties. Hence, understanding the PK and pharmacodynamics (PD) of a drug is crucial to assessing its (potential) DDIs [88] . This is mechanistically often explained by the fact that drugs share metabolic pathways, as has recently been discussed for the case of co-administering antituberculosis and antimalarial drugs, as is frequently the case in the developing world [89] .
The approaches taken to model DDIs have been presented in multiple recent studies. One such approach considers the structural similarity between query drugs and those involved in established DDIs to infer the possibility of adverse drug reactions (ADRs), and requires access to databases of known DDIs with similarity profiles that include 2D and/or 3D chemical structures, together with known interactions, targets and side-effects [87] .
Similarly, text mining has also been utilised for prediction of DDIs [90, 91] , and a recent review summarises these approaches [92] . Network-based approaches for predicting DDIs analyse the common targets and pathways involved with drug action, and correlate these with ADRs [93, 94] . Notable examples of this include the annotation and analysis of 45,180 DDIs of 1352 drugs [93] , and networks of Protein-Protein Interactions (PPIs) constructed for 1249 FDA-approved drugs that included 4776 associations to 1289 targets [94] . The main drawback of network-based approaches is an excessive number of assumptions that are made, which can ultimately decrease predictive capabilities. A comparison of dynamic and static models for the prediction of DDIs via inhibition mechanisms has shown similar performance between both approaches [95] . The aforementioned studies provide a set of well-annotated datasets for predictive combination models to train on, alongside extensive pathway and ADR annotations.
Traditional QSAR approaches are based on two key assumptions: (i) activity (property) is a function of structure; and (ii) similar structures will have similar properties. These approaches are attractive because after building a model it could be used for prediction of results of DDIs for millions of new combinations created by almost any drugs. QSAR modelling of DDIs using SiRMS [96] and GUSAR [97, 98] approaches was performed. To enable this approach, a combination of two drugs participating in DDIs was formally represented as a binary chemical mixture. Predictive models based upon $25,000 DDIs caused by more than 200 drugs were developed for inhibition of 1A2, 2C9, 2D6 and 3A4 -four major cytochrome P450 (CYP) isoforms. Because the validation of QSAR models for DDIs is more complicated than in traditional QSAR analysis, developed models were validated using a 'compounds out' strategy specially developed for rigorous validation of QSAR models of mixtures [99] . Predictions for more than half of the one million new DDIs were made using developed models.
Despite the plethora of different existing approaches for modelling DDIs, the prediction of new drug interactions, especially for complex medication regimens, remains an extremely challenging task that would still benefit from the development of new modelling approaches. Such models would require high-quality data to be trained upon, which cover multiple aspects of the known interactions between drugs. These datasets would benefit from the inclusion of target proteins for each compound, pathways that these targets are involved in, known resulting side-effects, bioavailability of the compounds and dosage levels. Additional information, such as the health, lifestyle and medication status of the individual from which this information is derived could prove in the future as modelling approaches become more refined. Although many tasks remain to be solved, once and where functioning, DDI modelling will be invaluable in guiding drug choice for combination therapy and hopefully result in fewer adverse effects.
Towards an improved understanding of compound combination effects: data integration, modelling and biological interpretability A key bottleneck in identifying and understanding the molecular effects of compound mixtures on a systems level is the integration of biological and chemical information. The strengths, weaknesses and the challenges of integrating data from disparate sources have been discussed [100] . Compound activity is detectable on multiple levels in the living system -phenotypically on the gene expression patterns and on the target interaction level as well [101] . Meaningfully combining diverse information requires an understanding of the specific context in which individual datasets have been devised. This diversity could also involve specific procedures followed, experimental platforms, disease area focus and to some extent the cultural differences at the source of this information as well. This variation becomes even more crucial and challenging to tackle in the case of compound combinations. In the context of this review, the data that need to be integrated for a comprehensive systems-level analysis to identify compound combinations efficiently include chemical bioactivity data [102] , targets and pathway annotations [80] , gene expression data [73] and protein interactions [103] . Along with these, annotations regarding negative and positive feedback loops in pathways would be significant in optimising the predictive model. Unfortunately, these annotations are not always available as a part of network biology resources and have to be extracted from publications. The challenge is not only to identify specific data sources that can be integrated but also to have a common identifier(s) that can connect these datasets. Although this can be reasonably achieved with a good level of accuracy and confidence for anecdotal cases, data integration on a global scale, towards obtaining a generalised systems level understanding, deals with a much higher level of complexity. For example, a limited number of select pathways involved in a certain disease type, along with chemical bioactivity data tested against protein targets specific to the involved pathways could be obtained [104] , but very rarely is information available on a larger scale. Cross-referencing at this level can be tedious, and in some cases meaningless. To predict compound combinations efficiently, comprehensive and quantitative data are key but often unavailable. At the same time, integrated relational databases are valuable in efficiently making biological and chemical predictions towards answering specific questions, for example generating MOA hypothesis for an observed phenotypic effect as a result of compound activity or identifying perturbation points along a given network(s) for identifying efficient drug combinations [16] and subsequent experimental validation. For this purpose, robust algorithms that consider and address the limitations of the integrated dataset are needed. Hence, careful consideration of the datasets and sources to be integrated is required, working towards answering the scientific questions of interest while enabling hypotheses and knowledge-driven analyses.
Challenges in the identification of useful compound combinations
Drug combinations provide many advantages in the treatment of diseases with complex aetiology, usually involving multiple targets and pathways. Even though drug combinations in some cases do lead to increased specificity [29] , concerns regarding the sideeffects of drug combinations still remain. Although this concern has been reported [105] , and observed in the case of teratogens [106] , several studies have not found evidence of such synergistic toxicities and indicate that the benefits of combinations outweigh the potential side-effects [107] [108] [109] . A notable concern when considering combination therapies in vivo is the role of PD, PK and interactions thereof in leading to unintended side-effects and/ or lack of efficacy [110] .
Although the reduction of drug-level-related side-effects is a key driver in the move to combination therapies, another limitation, in some cases, is that combination effects are dependent on the biological environment. In particular, synergies observed in vitro might not lead to effective combinations in vivo [50] . As an illustration, Brandl et al. [64] reported that synergism between vinblastine and kinesin spindle protein KSP/Eg5 inhibitors is observed in TNBC cells but not in normal fibroblasts. Even in the same biological setting, different routes of administration might or might not lead to synergistic effects. For example, Kolesnikov et al. [111] report that effects of topical combinations of analgesics mimic the effects of same combinations when administered systemically. By contrast, Banner and Press [107] report that oral administration of phosphodiesterase (PDE)3 and PDE4 inhibitors does not lead to synergistic effects, whereas an inhaled combination does. Thus, combinations offer many advantages but at the same time care must be taken to understand the systemic effects of drug combinations, as characterised by the PD and PK of the individual drugs and their effects on each other.
Concluding remarks
Compound combination studies integrating biological and chemical knowledge provide an opportunity for tackling key therapeutic and toxicity issues. Most prominently, these issues involve efficacy, drug resistance, side-effects and dosage tolerability in patients. These are problems that have always dogged the field of drug discovery but for which an efficient solution is yet to be achieved. Combination analyses studying chemical properties and bioactivity data do support and enhance the discovery of drugs that display better selectivity and possibility of overcoming drug resistance. However, the more we understand about this field the more numerous are the potential issues that surface. These include the possibility of undesired drug interactions, side-effects, biological selectivity where the combination works only in specific microenvironment and the differences in efficacy as a consequence of drug administration routes.
In the area of combination therapies, a deeper understanding of the underlying biological impact is required, such as that on gene expression and regulatory pathways. This can be achieved by integrating chemical bioactivity data from different realms of the biological system, viz. gene expression, gene-protein interaction networks and pathway annotations, among others. This approach can also assist in generating biologically meaningful MOA hypotheses for combinations of chemicals, and will help provide a comprehensive and solid foundation on which future chemical combination analyses could be performed. Such studies could have a significant impact on our understanding and applications of compound combinations. These include not only combination therapeutics but also pesticides, household chemicals and cosmetics that could otherwise have a potential health and environmental impact.
